Product Information
QC IBUPROFEN 200 MG SOFTGEL is a generic product labeled by Chain Drug Marketing Association, priced at $0.0762 per EA under NDC 83324020648. Its NADAC has been published 63 times since Jul 23, 2025.
FDA first approved this application on Mar 24, 2009.
Strength
200 mg/1
Manufacturer
Chain Drug Marketing AssociationNDC
83324020648
Classification
Generic
Dosage Form
CAPSULE, LIQUID FILLED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA078682FDA Approved
3/24/2009
On Market Since
6/20/2025
Pharmacological Classes
Price Statistics
The NADAC for QC IBUPROFEN 200 MG SOFTGEL has been published 63 times since Jul 23, 2025, and over the history we have for it it has declined 4.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0762 per EA |
|---|---|
| All-time high | $0.0816 (Jul 15, 2026) |
| All-time low | $0.0762 (Sep 23, 2026) |
| 52-week high | $0.0816 |
| 52-week low | $0.0762 |
| Median price | $0.0799 |
| Average price | $0.0797 |
| Largest weekly change | -4.0% (Aug 19, 2026) |
| Weeks tracked | 63 |
| Tracking since | Jul 23, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chain Drug Marketing Association manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QC IBUPROFEN 200 MG SOFTGEL?
The current National Average Drug Acquisition Cost (NADAC) for QC IBUPROFEN 200 MG SOFTGEL, manufactured by Chain Drug Marketing Association, is $0.0762 per EA (NDC 83324020648), effective Sep 30, 2026.
How has the price of QC IBUPROFEN 200 MG SOFTGEL changed over time?
Over the history we have for it, the NADAC for QC IBUPROFEN 200 MG SOFTGEL has declined 4.1%. It has been tracked across 63 weekly CMS publications since Jul 23, 2025.
What are the highest and lowest recorded NADAC prices for QC IBUPROFEN 200 MG SOFTGEL?
Since Jul 23, 2025, the NADAC for QC IBUPROFEN 200 MG SOFTGEL has ranged from a low of $0.0762 (Sep 23, 2026) to a high of $0.0816 (Jul 15, 2026), with a median of $0.0799 per EA.
Are there cheaper alternatives to QC IBUPROFEN 200 MG SOFTGEL?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as QC IBUPROFEN 200 MG SOFTGEL in a comparable dosage form, but none are currently priced below it.
Who manufactures QC IBUPROFEN 200 MG SOFTGEL?
QC IBUPROFEN 200 MG SOFTGEL (NDC 83324020648) is labeled by Chain Drug Marketing Association, and CMS classifies it as a generic product.